Elevated lipoprotein(a) levels (Lp(a) ≥50 mg/dL) are associated with a significantly higher risk of incident venous thromboembolism (VTE), according to a retrospective cohort study published in JAMA Cardiology.
Evidence of Lp(a) and Venous Thromboembolism
Historically, medical research has focused on Lp(a) as a driver of arterial disease. However, the study led by Luke Dreher, MD, an internal medicine resident in the department of cardiovascular medicine at Mayo Clinic Arizona, sought to clarify its role in venous events. By analyzing 69,214 patients between 1997 and 2026, investigators found that 2.2% of the cohort experienced incident VTE.
Data showed that patients with Lp(a) levels of 50 mg/dL or higher had a crude VTE rate of 2.8%, compared to 1.9% in those with lower levels. Even after accounting for variables such as active cancer and major thrombophilia, the association remained statistically significant. The study observed that higher thresholds of Lp(a) corresponded to greater effect sizes; specifically, patients with levels at or above 150 mg/dL faced an adjusted odds ratio of 2.66 for VTE.
Clinical Implications for Future Lp(a) Research
The findings suggest that the biological impact of Lp(a)—which includes potential antifibrinolytic and prothrombotic properties—extends beyond arterial walls. Dreher and his colleagues noted that the persistence of this association in patients without hypercoagulability markers implies that Lp(a) acts as an independent factor in venous events.
As these treatments move into broader clinical use, researchers suggest that future trials should consider monitoring venous outcomes in addition to the standard focus on arterial disease.
Study Methodology and Limitations
The investigation utilized data from the Mayo Clinic Enterprise, relying on the first routine-care Lp(a) measurement for each patient as an index value. While the results demonstrate a clear statistical signal, the researchers identified several limitations inherent to the study design.
- Retrospective Design: The study relied on historical data rather than prospective intervention.
- Testing Variability: Lp(a) measurements were clinically triggered in a tertiary care setting, meaning there were no standardized indications for testing.
- Documentation: Outcomes were identified through text-based extraction of medical records rather than direct clinical adjudication.
- Cohort Demographics: The study population was predominantly white, which may limit the generalizability of the findings to more diverse populations.
Elevated Lp(a) levels and venous thromboembolism risk
Does high Lp(a) only affect arterial health? No. While it is a well-established risk factor for arterial disease, the recent Mayo Clinic study confirms a distinct, consistent association between elevated Lp(a) and venous thromboembolism (VTE).
How much does Lp(a) increase VTE risk? The study found that for every 10 mg/dL increase in Lp(a), there was a corresponding 5% increase in the adjusted odds of VTE. At levels of 150 mg/dL or higher, the adjusted odds ratio reached 2.66.
Did the study include patients with cancer? The researchers performed sensitivity analyses that excluded patients with active cancer and major thrombophilia. The association between elevated Lp(a) and VTE remained unchanged, indicating that the risk is not solely driven by these hypercoagulable states.
What is the next step for Lp(a) research? Authors of the study recommend prospective research to further investigate venous outcomes. They also suggest that upcoming clinical trials for Lp(a)-lowering therapies should incorporate VTE monitoring into their primary or secondary endpoints.